{"id":547035,"date":"2021-06-10T14:26:02","date_gmt":"2021-06-10T14:26:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=547035"},"modified":"2021-06-10T14:26:02","modified_gmt":"2021-06-10T14:26:02","slug":"psoriatic-arthritis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-sun-pharma-global-ucb-biopharma-pfizer-bristolmyers-squibb-abgenomics-boehringer-ingelheim","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-sun-pharma-global-ucb-biopharma-pfizer-bristolmyers-squibb-abgenomics-boehringer-ingelheim_547035.html","title":{"rendered":"Psoriatic Arthritis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Sun Pharma Global, UCB Biopharma, Pfizer, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1623323427.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Psoriatic Arthritis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Sun Pharma Global, UCB Biopharma, Pfizer, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim\" src=\"https:\/\/www.abnewswire.com\/uploads\/1623323427.jpeg\" alt=\"Psoriatic Arthritis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Sun Pharma Global, UCB Biopharma, Pfizer, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Psoriatic Arthritis Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Psoriatic Arthritis<\/a><\/strong> is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling. Psoriatic arthritis is considered as seronegative spondyloarthropathies. The fact that it is Seronegative is that the blood tests negative for some factors that is present in rheumatoid arthritis. Spondyloarthropathy describes a group of conditions that all share common characteristics. First, there is a presence of arthritis that affects the spine. Second, inflammation occurs in ligaments, tendons and sometimes in other organs such as the eye.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Psoriatic arthritis Pipeline<\/strong><strong> Insight, 2021<\/strong>&rdquo; report provides comprehensive insights about <strong>35+ companies and 35+ pipeline drugs<\/strong> in Psoriatic arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Psoriatic Arthritis Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Sun Pharma Global<\/li>\n<li>UCB Biopharma<\/li>\n<li>Pfizer<\/li>\n<li>Bristol-Myers Squibb<\/li>\n<li>AbGenomics<\/li>\n<li>Boehringer Ingelheim<\/li>\n<li>Affibody<\/li>\n<li>AltruBio<\/li>\n<li>Synact Pharma<\/li>\n<li>NeuClone<\/li>\n<li>3SBio<\/li>\n<li>Qyuns Therapeutics<\/li>\n<li>Kangpu Biopharmaceuticals<\/li>\n<li>Alpine Immune Sciences<\/li>\n<li>Avotres<\/li>\n<li>Xbrane Biopharma<\/li>\n<li>XBiotech<\/li>\n<li>Evelo<\/li>\n<li>Luye Pharma Group<\/li>\n<li>Levolta Pharmaceuticals<\/li>\n<li>DNX Biopharmaceuticals<\/li>\n<li>Mycenax Biotech<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>Psoriatic Arthritis report<\/strong> covers around 35+ products under different phases of clinical development like<\/p>\n<ul style=\"text-align: justify;\">\n<li>Late stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Psoriatic Arthritis Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Tildrakizumab<\/li>\n<li>Bimekizumab<\/li>\n<li>PF-06700841<\/li>\n<li>BMS-986165<\/li>\n<li>AbGn-168H<\/li>\n<li>BI 730357<\/li>\n<li>Izokibep<\/li>\n<li>Neihulizumab<\/li>\n<li>AP1189<\/li>\n<li>NeuLara<\/li>\n<li>Apremilast<\/li>\n<li>QX 002N<\/li>\n<li>KPG-612<\/li>\n<li>ALPN 101<\/li>\n<li>AVT001<\/li>\n<li>Xcimzane<\/li>\n<li>RHE 70202<\/li>\n<li>EDP1815<\/li>\n<li>DNX 514<\/li>\n<li>DNX 114<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Psoriatic Arthritis Treatment Scenario and Psoriatic Arthritis Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Psoriatic arthritis drugs?<\/li>\n<li>How many Psoriatic arthritis drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Psoriatic arthritis?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Psoriatic arthritis therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Psoriatic arthritis and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: https:\/\/www.delveinsight.com\/sample-request\/psoriatic-arthritis-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<br \/> Executive Summary<br \/> Psoriatic arthritis: Overview<br \/> Pipeline Therapeutics<br \/> &bull; Comparative Analysis<br \/> Therapeutic Assessment<br \/> Psoriatic arthritis &ndash; DelveInsight&rsquo;s Analytical Perspective<br \/> In-depth Commercial Assessment<br \/> &bull; Psoriatic arthritis companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends<br \/> Psoriatic arthritis Collaboration Deals<br \/> Late Stage Products (Preregistration)<br \/> &bull; Comparative Analysis<br \/> Tildrakizumab: Sun Pharma Global<br \/> Drug profiles in the detailed report&hellip;..<br \/> Mid Stage Products (Phase II) <br \/> &bull; Comparative Analysis<br \/> BMS-986165: Bristol-Myers Squibb<br \/> Drug profiles in the detailed report&hellip;..<br \/> Early Stage Products (Phase I) <br \/> &bull; Comparative Analysis<br \/> Apremilast: 3SBio<br \/> Drug profiles in the detailed report&hellip;..<br \/> Preclinical and Discovery stage Products<br \/> &bull; Comparative Analysis<br \/> ALPN 101: Alpine Immune Sciences<br \/> Drug profiles in the detailed report&hellip;..<br \/> Inactive Products<br \/> &bull; Comparative Analysis<br \/> Psoriatic arthritis Key Companies<br \/> Psoriatic arthritis Key Products<br \/> Psoriatic arthritis- Unmet Needs<br \/> Psoriatic arthritis- Market Drivers and Barriers<br \/> Psoriatic arthritis- Future Perspectives and Conclusion<br \/> Psoriatic arthritis Analyst Views<br \/> Psoriatic arthritis Key Companies<br \/> Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=psoriatic-arthritis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-sun-pharma-global-ucb-biopharma-pfizer-bristolmyers-squibb-abgenomics-boehringer-ingelheim\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/psoriatic-arthritis-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=psoriatic-arthritis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-sun-pharma-global-ucb-biopharma-pfizer-bristolmyers-squibb-abgenomics-boehringer-ingelheim\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Psoriatic Arthritis Pipeline Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/psoriatic-arthritis-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-sun-pharma-global-ucb-biopharma-pfizer-bristolmyers-squibb-abgenomics-boehringer-ingelheim_547035.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-547035","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/547035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=547035"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/547035\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=547035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=547035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=547035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}